Akers Bio stock price plummets after company withdraws product applications

Akers Biosciences Inc. said Monday it is withdrawing, at the recommendation of the Food and Drug Administration, the company's application seeking approval for a product it is developing to rapidly diagnose a common sexually transmitted disease. The Thorofare, N.J., medical-device company said it's pulling the application for its PIFA (Particle Immuno-Filtration Assay) Chlamydia product in order to re-evaluate its options. The rapid diagnostic test device is designed to test patients for chlamydia…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news